FDA approves tirzepatide under new brand name for chronic weight management

Today, the FDA approved tirzepatide (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition (such as high BP, T2DM, or high cholesterol) for use with a reduced calorie diet and increased physical activity. Tirzepatide is already approved under the trade name Mounjaro for use with diet and exercise in adults with T2DM. Zepbound is given via SC injection starting at 2.5 mg once weekly, with dosage increments over four to 20 weeks to achieve target dosages of 5, 10, or 15 mg once weekly.